ReviewBiomedicines2023
Mesenchymal Stem Cell in Pancreatic Islet Transplantation.
Review in Biomedicines, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it.
- A meta-analysis on application and prospect of cell therapy in the treatment of diabetes mellitus.Stem cell research & therapy · 2025Pooled it
- Role of the Proteasome System in Shaping Cellular Immunological Characteristics and Its Impact in Modulating the Pathogenesis of Immune-Related Diseases.Cells, tissues, organs · 2026Review
- Enhancing islet transplantation outcomes in T1DM: The promise of mesenchymal stem cells and exosomes.International journal of pharmaceutics: X · 2026Review
- Review
- Preventing the onset of diabetes with precision delivery of mesenchymal stem cells to the pancreas in a preclinical model.Stem cell research & therapy · 2025Article
- R-spondins secreted by human pancreas-derived mesenchymal stromal cells support pancreatic organoid proliferation.Cellular and molecular life sciences : CMLS · 2025Article
- Article
- Human mesenchymal stem/stromal cell based-therapy in diabetes mellitus: experimental and clinical perspectives.Stem cell research & therapy · 2024Review
- Review
- Precision Delivery of Human Bone Marrow-Derived Mesenchymal Stem Cells Into the Pancreas Via Intra-arterial Injection Prevents the Onset of Diabetes.Stem cells translational medicine · 2024Article
- Enhancing human islet xenotransplant survival and function in diabetic immunocompetent mice through LRH-1/NR5A2 pharmacological activation.Frontiers in immunology · 2024Article
- The potential of cellular homing behavior in tumor immunotherapy: from basic discoveries to clinical applications of immune, mesenchymal stem, and cancer cell homing.Frontiers in immunology · 2024Review
- Advancements in innate immune regulation strategies in islet transplantation.Frontiers in immunology · 2023Review
- Subcutaneous device-free islet transplantation.Frontiers in immunology · 2023Review
- Advances in stem cell-derived beta-cell therapy: A new frontier in type 1 diabetes treatment.Cell transplantationReview
- A novel approach for hepatocyte transplantation at the liver surface.Cell transplantationArticle
- A novel method of pancreatic islet transplantation at the liver surface using a gelatin hydrogel nonwoven fabric.Cell transplantationArticle
- Molecular mechanisms responsible for mesenchymal stem cell-dependent improvement of islet cell transplantation.Cell transplantationReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pancreatic islet transplantation is a therapeutic option for achieving physiologic regulation of plasma glucose in Type 1 diabetic patients. At the same time, mesenchymal stem cells (MSCs) have demonstrated their potential in controlling graft rejection, the most fearsome complication in organ/tissue transplantation. MSCs can interact with innate and adaptive immune system cells either through direct cell-cell contact or through their secretome including exosomes. In this review, we discuss current findings regarding the graft microenvironment of pancreatic islet recipient patients and the crucial role of MSCs operation as cell managers able to control the immune system to prevent rejection and promote endogenous repair. We also discuss how challenging stressors, such as oxidative stress and impaired vasculogenesis, may jeopardize graft outcomes. In order to face these adverse conditions, we consider either hypoxia-exposure preconditioning of MSCs or human stem cells with angiogenic potential in organoids to overcome islets' lack of vasculature. Along with the shepherding of carbon nanotubes-loaded MSCs to the transplantation site by a magnetic field, these studies look forward to exploiting MSCs stemness and their immunomodulatory properties in pancreatic islet transplantation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.